A pioneer in human metabolic research and world leader in new diagnostic technologies in metabolic disease, including co-invention of the MAT, with 350 scientific publications, 55 issued international patents and extensive experience in drug development.
A renowned expert in aging and muscle (he was the first to describe the condition, sarcopenia) and co-inventor of MAT with over 350 scientific publications.
MyoCorps’ initial strategy is to gain FDA clearance for the MAT in specific medical conditions related to aging, mobilty, strength and skeletal muscle dysfunction. By using MyoCorps’ patented MAT, health care providers can identify people with low muscle mass that contributes to reduced strength and performance. The goal is to empower healthier aging through cutting-edge muscle mass diagnostics.
The first medical indication that MyoCorps is pursuing is an FDA clearance for diagnosis of patients with mobility disability (ICD 10 code R54) that is caused by low muscle mass.
Over the longer term, we envision muscle mass measured by the MAT to be a test that is routinely measured in almost everyone, much like cholesterol, blood sugar and an EKG are today. Applications of the MAT in many areas can be envisioned, ranging from growth curves in children, competitive athletics, monitoring benefit of exercise and dietary programs by gyms, trainers and nutritionists, and assessing clinical response to medical management and in drug development.
Copyright © 2025 by MyoCorps | All Rights Reserved.
